A Prospective Randomised Phase III Study of Androgen Deprivation Therapy (+/- Docetaxel) With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer

Trial Profile

A Prospective Randomised Phase III Study of Androgen Deprivation Therapy (+/- Docetaxel) With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; LHRH receptor agonists; LHRH receptor antagonists; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms GETUG AFU 21; PEACE1
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Jun 2016 Docetaxel drug is added hence Study Title has been changed.
    • 28 Jun 2016 Planned primary completion date changed from 1 Oct 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top